Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 6 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.

Celecoxib better than diclofenac sodium for knee osteoarthritis

08 Sep 2020

Patients with knee osteoarthritis may experience better pain relief with celecoxib than with diclofenac sodium, in addition to having lower levels of inflammatory markers and complication risk, a study has found.

Researchers performed a systematic review and meta-analysis of 12 trials comparing the efficacy of the two painkillers in terms of knee pain, C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), visual analogue scale (VAS) score, and complication rate.

There were 2,350 individuals included in the studies, with 1,189 in the celecoxib group and 1,161 in the diclofenac sodium group. Pooled data showed that treatment efficacy (rate graded as follows: clinically controlled, significantly improved, improved, or ineffective) was substantially greater with celecoxib (odds ratio [OR], 3.40, 95 percent confidence interval [CI], 2.17–5.32; p≤0.001), with good statistical homogeneity among the studies (I2, 17.3 percent).

In terms of pain (assessed using the VAS score), celecoxib likewise proved more effective than diclofenac sodium (standardized mean difference [SMD], −1.44, 95 percent CI, −2.27 to −0.60; p≤0.001), with high heterogeneity.

Celecoxib also showed superiority to the other drug with respect to reducing CRP (SMD, −9.73, 95 percent CI, −15.75 to −3.72; p=0.002) and ESR (SMD, 5.56, 95 percent CI, 2.05–9.06; p=0.002), and the incidence of complications (OR, 0.34, 95 percent CI, 0.20–0.59; p≤0.001).

The findings suggest that celecoxib may favourably impact treatment of knee osteoarthritis by reducing pain, inflammatory markers and incidence of complications. Nevertheless, well-designed and high-quality trials are still needed.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 6 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.